This study is a double blind randomized clinical trial. The goal of our study is to determine the effects of symbiotic on inflammatory markers, liver function, lipid profile, sonographic findings and body composition in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). A sample of 80 NAFLD patients aged 18-60 years will be enrolled in the study. The exclusion criteria are other chronic liver diseases, Inflammatory Bowel Diseases, Diabetes Mellitus, Cancer, consumption of some drugs or supplements. The patients by Block Randomization for age, sex, Body Mass Index (BMI) and Livergol or Metformin consumption, will be randomized to one of the two treatment and control groups. Patients in the first group will be treated with one tablet of synbiotic supplement contain 500 mg of seven Probiotic bacteria species and Fructooligosaccharides per day and control group will be treated with one placebo tablet per day. Physical activity and dietary recommendation will be given to both groups. The intervention will continue for 8 weeks. Liver Ultrasonography, routine liver tests, lipid profile, inflammatory markers and body composition will be evaluated on baseline and again after the intervention. Dietary intake and physical activity status will be determined by dietary record and physical activity record on the end of weeks 2, 4 and 6.